Pharmacy Data for Tuberculosis Surveillance and Assessment of Patient Management
Deborah S. Yokoe* , Steven W. Coon†, Rachel Dokholyan‡, Michael C. Iannuzzi†, Timothy F. Jones§, Sarah Meredith¶, Marisa Moore#, Lynelle Phillips**, Wayne Ray¶, Stephanie Schech††, Deborah Shatin††, and Richard Platt*†‡‡
Author affiliations: *Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA; †Henry Ford Health System, Detroit, Michigan, USA; ‡Harvard Pilgrim Health Care, Boston, Massachusetts, USA; §Tennessee Department of Health, Nashville, Tennessee, USA; ¶Center for Education and Research in Therapeutics and Vanderbilt University, Nashville, Tennessee, USA; #Centers for Disease Control and Prevention, Atlanta, Georgia, USA; **Missouri Department of Health and Senior Services, Jefferson City, Missouri, USA; ††Center for Health Care Policy and Evaluation, Minneapolis, Minnesota, USA; and; ‡‡HMO Research Network Center for Education and Research on Therapeutics, Boston, Massachusetts, USA
Figure 1. Sensitivity and positive predictive value (PPV) of pharmacy screening and percentage of tuberculosis (TB) cases detected only by pharmacy screening. *Of 28 members who met pharmacy screening criteria, TB case status was verified for 14. PPV calculation based on total of 14 with verified status. **Health plan–treated patients excludes patients receiving anti-TB medication from public health clinics
The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.